Customer termination and weak contractual lock-in
Many agreements are not long-term and some consignment deals can be ended with short notice.
- Scope
- Hospital and clinic customers
- Materiality
- high
TriSalus Life Sciences, Inc.
TriSalus Life Sciences is a U.S.-based medical device company focused on catheter-based infusion systems used in interventional oncology procedures. Its core product platform, TriNav, is designed for delivery in embolization workflows and is sold directly to hospitals, clinics, and physicians in the United States.
−58,3 %
84,6 %
−86,9 %
+53,4 %
2.80
2.54
| % | |
|---|---|
| TriNav infusion devices | 90% Catheter-based infusion devices used in embolization procedures, primarily TriNav. |
| PEDD infusion systems | 10% Infusion systems sold for interventional radiology and oncology procedures. |
TriSalus sells directly to hospitals, clinics, and ambulatory surgery centers that perform embolization procedures,...
- Hospitals and academic medical centersprimary
Buy TriNav for embolization procedures and evaluate it through clinical and procurement committees.
- Interventional radiologistsprimary
Use the device in TACE, TARE, and related procedures and influence adoption.
- Medical oncologists and oncology teamssecondary
Support treatment planning for liver cancer patients and may recommend use.
- Ambulatory surgery centers and clinicssecondary
Purchase devices for outpatient or clinic-based interventional procedures.
- Value Analysis Committeesprimary
Review clinical and economic justification before hospital adoption.
TriSalus is headquartered in Westminster, Colorado and sells primarily in the United States through a direct sales...
- •Headquartered in Westminster, Colorado
- •Primary market is the United States
- •Direct sales model reaches hospitals nationwide
- •Focus on major academic medical centers and procedure-heavy hospitals
TriSalus’ strategy centers on expanding adoption of TriNav among interventional radiologists and hospital systems...
01
Expand TriNav adoption in embolization proceduresshort-term
Procedure volume and physician familiarity drive recurring device usage.
02
Strengthen hospital and clinician relationshipsshort-term
Hospital purchasing depends on clinical trust and committee approval.
03
Support broader interventional oncology positioningmedium-term
Clinical and advocacy relationships can widen awareness and use cases.
TriSalus faces the risks typical of an early-stage medical device company, including customer concentration, limited...
Dependence on physician adoption
Interventional radiologists and hospital committees influence whether TriNav is used.
- Scope
- Procedure-based demand
- Materiality
- high
Regulatory and reimbursement risk
Device use and hospital economics depend on healthcare regulation and payment support.
- Scope
- U.S. hospital purchasing
- Materiality
- high
Financing and liquidity risk
The company has not yet generated enough cash from operations to fund growth.
- Scope
- Capital markets access
- Materiality
- high
Competitive and technological change
The medical device market changes quickly and larger competitors may offer alternatives.
- Scope
- Interventional oncology devices
- Materiality
- high
Supply-chain and cybersecurity disruption
The company relies on third parties for manufacturing, systems, and clinical operations.
- Scope
- Manufacturers, cloud systems, and contractors
- Materiality
- medium
Revenue recognition on consignment and direct sales
Can shift revenue between periods
Customer rebates
Reduces net sales and can affect quarterly comparability
Fair value of SEPA, warrant, and earnout liabilities
Can materially affect reported net loss
Manufacturing cost and inventory estimates
Affects gross margin and operating leverage
: 29.4.2026